Category Archives: Business and Investments

Latest From Business and Investments

BIO Europe Spring 2012 – Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public market performance in the US vs other sectors Private funding environment. Drug pipeline deal volume. For a copy of the slides, they can be found here.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

Exhibitor Partnering: A Toolkit


Traditionally, all private meetings at the BIO International convention have taken place in the BIO Business Forum®. If you were partnering, you would be found in a booth space within the Business Forum, end of story. This year, however, there’s Exhibitor Partnering, a completely new feature of the BIO International Convention and the BIO Business Forum. The Business Forum will still very much exist, and you can see exactly where in the map below of Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Does Biotech History Repeat?


According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he know that one day that would hold true for something called “Biotech”. Indeed, there seems to be a lot of rhyming going on with Biotech IPOs today with recent history. When we compare the accumulated number of IPOs in the last IPO window (2003-2007) with the current window (2009-now), we see an amazing overlay. Not identical, but not too far from it. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Sen. Bob Menendez & William Waddill on the Therapeutic Discovery Project


Senator Bob Menendez (D-NJ), at the March 6th Senate Banking, Housing and Urban Affairs hearing, emphasizes the effectiveness of the 2010 Therapeutic Discovery Project, the need to extend the program, and asks William Waddill, CFO/SVP of OncoMed Pharmaceuticals to share his company’s success story as a result of receiving an award. Read testimony from Waddill on the importance of capital formation.

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Update: Indices, IPOs, and New Drug Approvals


Here is a look at year to date (YTD) numbers through the end of February for the biotech indices, initial public offerings, and recent FDA Approvals. 1. Indices: The Nasdaq Biotech Index held the January jump through February, settling at + 14% YTD. The concentrated BTK slipped in February, but has outpaced the NBI since January 1st. YTD, both biotech indices have significantly outperformed the broader market. In contrast, the NYSE Pharmaceuticals Index has not Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , ,